The clinical results stem from an extension of a Phase 2a study, which initially enrolled 24 participants in Australia. Following the primary 24-week evaluation, some patients continued receiving a 300mg daily dose of tazbentetol under a compassionate use Special Access Scheme. Data indicates that the positive cognitive shifts observed early in the trial—such as improved scores on the Standardized Mini-Mental Status Examination—did not plateau, but persisted through the 19-month mark.

Spinogenix highlighted the case of a 72-year-old patient whose caregivers reported a marked return of social skills and reading comprehension within three months of starting the medication. These observations aligned with clinical metrics, including a sustained decrease in the Clinical Dementia Rating Scale Sum of Boxes scores. Dr. Stella Sarraf, CEO of Spinogenix, noted that the data reinforces the drug's potential as a well-tolerated, long-term intervention for neurodegenerative conditions. The company is currently planning subsequent trials to further evaluate the therapy, which aims to restore depleted synapses rather than merely slowing disease progression.